Presage Biosciences is a pioneer in translational oncology, dedicated to bringing innovation to cancer drug development. Their patented CIVO (Comparative In Vivo Oncology) platform allows the observation of tumor microenvironmental responses to multiple investigational treatments within a patient's tumor, bridging preclinical insights and patient care. This unique platform offers comprehensive insights into the tumor microenvironment and is vital in evaluating multiple drug candidates and combinations simultaneously in cancer patients, providing detailed cell and molecular profiling.

Presage’s mission is to improve the development and targeting of new drugs, ultimately aiming to provide more effective cancer treatments. The company has nine issued US patents and aims to provide a pioneering solution to fundamental problems in oncology drug discovery. Equipped with a skilled team, advanced technology, and in-house expertise, Presage is leading the way in predictive platforms for testing candidate agents and pioneering solutions for translational oncology research.

Presage Biosciences strives to fundamentally change cancer drug development by improving the way new drugs are developed and targeted